hrs-1893
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Jun 5, 2023 (NCT05879523)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07272330 | Phase 1 | Dec 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07269717 | Phase 2 | Dec 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07021976 | Phase 3 | Aug 11, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07021963 | Phase 2 | Jul 4, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT07033455 | Early Phase 1 (Phase 1) | Jun 25, 2025 | Atridia Pty Ltd. |
| NCT06816251 | Phase 2 | Feb 25, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06775834 | Phase 1 | Jan 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06516068 | Phase 2 | Jul 31, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06354556 | Phase 1 | Apr 26, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05879523 | Phase 1 | Jun 5, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 9 | 9 | 3 | 2023 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1